Blog
About

0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The safety of tumor necrosis factor-alpha (TNF-α) inhibitors in the setting of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections is controversial. The use of anti-TNF-α in rheumatoid arthritis (RA) is associated with an increased risk of hepatitis re-activation. This paper reports experience of using etanercept and adalimumab in 32 patients with RA and previous HBV or HCV infection. No cases of HBV or HCV reactivation were seen. In just over a fifth of patients, increased transaminases levels were seen, which were associated with concomitant use of disease-modifying antirheumatic drugs, isoniazid prophylaxis, or alcohol abuse. In our experience, anti-TNF-α therapy appears to be safe in RA patients with previous HBV or HCV infection, but monitoring remains necessary in these patients.

          Related collections

          Author and article information

          Journal
          Drug Dev. Res.
          Drug development research
          0272-4391
          0272-4391
          Nov 2014
          : 75 Suppl 1
          Affiliations
          [1 ] Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi,", University of Rome Tor Vergata, Roma, 00133, Italy.
          Article
          10.1002/ddr.21193
          25381975
          © 2014 Wiley Periodicals, Inc.

          hepatitis C, anti-TNF, hepatitis B, rheumatoid arthritis

          Comments

          Comment on this article